Fudan University Shanghai Cancer Center (FUSCC)
Established in 1931 as China's first dedicated cancer institution, FUSCC has grown into one of the country's most comprehensive oncology hospitals โ with 2,149 beds, 43 clinical departments, proton and heavy ion therapy, a national-level breast cancer centre, and over 300 SCI-indexed research papers published annually alongside formal academic partnerships with MD Anderson, Gustave Roussy, Princess Margaret, and five other global cancer leaders.
About Fudan University Shanghai Cancer Center
Fudan University Shanghai Cancer Center (FUSCC), formally established on 1 March 1931 as the Sino-Belgian Radium Institute, is the oldest dedicated cancer hospital in China and one of the country's most respected comprehensive oncology institutions. Operating under the Shanghai Medical College of Fudan University, FUSCC holds Grade 3 Class A status โ the highest designation in China's hospital quality classification system โ and is supervised directly by the National Health Commission as a budget management hospital jointly trustee-built by the Ministry of Education, the National Health Commission, and the Shanghai Municipal Government.
The hospital operates across two main campuses: the primary clinical campus in Xuhui District and the Shanghai Proton and Heavy Ion Hospital in Pudong New Area โ the first proton and heavy ion cancer treatment facility in mainland China, offering one of the most advanced radiation therapy platforms available in Asia. Together, the two sites host 43 clinical and technical departments, 2,149 operational beds, and a staff of approximately 2,979, including research faculty, clinical oncologists, surgeons, and radiation specialists. Key academic disciplines recognised at national level include oncology, pathology, and TCM-WM integrated medicine, with breast oncology, radiotherapy, and pathology additionally designated as national key clinical specialties under the National Health Commission.
FUSCC is particularly renowned for its Breast Oncology Centre โ a nationally recognised programme that has defined precision treatment strategies for triple-negative breast cancer and is led by Professor Shao Zhimin, one of China's foremost breast oncologists. The Pancreatic Tumour Centre, established in 2010, performs approximately 2,500 surgeries annually with a leading minimally invasive programme and the internationally recognised 'Fudan approach' to pancreatic surgery. Additional clinical strengths include thoracic surgery (lung and oesophageal), head and neck oncology, gastric and colorectal surgery, hepatic surgery, and a dedicated radiation oncology programme benefiting from the Pudong proton/heavy ion facility.
Academically, FUSCC has established formal sister-institution partnerships with eight leading global cancer centres: MD Anderson Cancer Center (USA), Institut Gustave Roussy (France), Duke Cancer Institute (USA), European Institute of Oncology (Italy), National University Cancer Institute Singapore, Cancer Research Institute of Kanazawa University (Japan), Peter MacCallum Cancer Centre (Australia), and The Princess Margaret Cancer Centre (Canada). These partnerships support bilateral clinical exchange, research collaboration, and referral protocols โ ensuring FUSCC's clinical practices remain aligned with international evidence standards. The hospital publishes over 300 SCI-indexed papers annually in journals including Nature, Journal of Clinical Oncology, and JNCI.
For international cancer patients, CancerFax acts as a dedicated coordination bridge to FUSCC. Our clinical team reviews your medical records, prepares a structured oncology summary for the appropriate department, identifies the right specialist based on your tumour type and treatment history, and coordinates consultation scheduling, cost estimation, visa support, and logistics โ so you arrive with a confirmed plan rather than uncertainty.
| Hospital at a Glance | |
|---|---|
| Country | China |
| City | Shanghai (Xuhui District main campus; Pudong โ Proton/Heavy Ion) |
| Established | 1931 (Sino-Belgian Radium Institute) |
| Hospital Grade | Grade 3, Class A (highest in China) |
| Accreditation | National Health Commission Supervised โ Ministry of Education Key Hospital |
| Beds | 2,149 in operation (2023) |
| Staff | ~2,979 (clinical, research, technical, administrative) |
| Departments | 43 clinical and technical departments |
| Research Output | 300+ SCI papers annually |
Why Patients Choose This Hospital
Cancer Specialties and Clinical Departments
Advanced Treatment Capabilities
Our Medical Specialists
FUSCC's clinical faculty includes nationally and internationally recognised oncology specialists across all major tumour types. The breast oncology team, led by Professor Shao Zhimin, is a national reference programme. The Head and Neck Surgery department is led by Professor Ji Qinghai, with over 30 years of clinical and research leadership in thyroid, laryngeal, and pharyngeal cancers. The pancreatic surgery team performs among the highest volumes of pancreatic and periampullary resections in China annually. Gastric surgery, thoracic surgery, and radiation oncology departments hold national key specialty designations under the National Health Commission.
Across departments, FUSCC physicians are active in international collaborations through the hospital's eight sister-institution partnerships โ many having trained at or published jointly with MD Anderson, Gustave Roussy, Duke, and other global leaders. The research faculty publishes over 300 SCI papers annually and leads Phase II/III trials in breast, lung, gastric, and pancreatic cancers.
Patients seeking specific physician consultations may request a speciality-matched oncologist recommendation through CancerFax's coordination process before confirming travel or admission.
World-Class Infrastructure
- Carbon ion (heavy ion) therapy โ highest biological effectiveness for radio-resistant tumours
- Proton therapy โ precise dose delivery with Bragg peak, minimal exit dose
- Integrated with FUSCC's clinical tumour boards for multidisciplinary radiation planning
- First proton and heavy ion facility in mainland China โ established clinical programme
- Three Shanghai key laboratories: breast cancer, pancreatic cancer, radiation oncology
- Shanghai Pathological Diagnosis Clinical Medical Research Center
- Comprehensive NGS-based molecular profiling and biomarker testing
- National drug clinical trial agency โ Phase I/II/III trial infrastructure
- Affiliated with Shanghai Pathology and Radiotherapy Quality Control Center
- 26 dedicated surgical oncology departments
- Minimally invasive and laparoscopic procedures across gastric, colorectal, hepatic, and thoracic cancer surgery
- Pancreatic Tumour Centre performing ~2,500 surgeries annually
- Da Vinci robotic surgical system for selected urological and thoracic procedures
- Multidisciplinary surgical planning through departmental tumour boards
- Medical oncology with access to all NMPA-approved targeted agents and immunotherapy
- Clinical trial programme including early-phase investigational therapies
- National-level clinical discipline designation in oncology and TCM-WM integrated medicine
- PD-1 inhibitor programme (nivolumab, sintilimab, camrelizumab), ADC therapy (T-DXd, RC48)
- Dedicated clinical pharmacy and chemotherapy administration unit
Services for International Patients
- arrow_rightCompile all available medical records โ pathology (including IHC and NGS results), imaging (CT, MRI, PET-CT as DICOM if possible), surgical/operative reports, prior treatment summaries, and current medications โ and share with CancerFax for review before booking.
- arrow_rightAllow CancerFax to prepare a structured oncology summary in the format expected by FUSCC's relevant department. This ensures your case is reviewed by the right specialist and reduces administrative delays on arrival.
- arrow_rightApply for a Chinese medical visa ('Medical Attendant Visa' for accompanying family members) after receiving the FUSCC invitation letter โ typically issued within 3โ5 working days of a confirmed appointment.
CancerFax manages the full pre-arrival and in-country coordination with FUSCC's International Patient Office. Patients and families deal with a single point of contact throughout.
Patient Amenities & Facilities
Family members accompanying international patients can stay in nearby hotels in Xuhui District (adjacent to the main campus) or in Pudong (adjacent to the Proton & Heavy Ion Hospital). CancerFax assists with accommodation recommendations based on the campus relevant to the patient's treatment programme.
How to Reach This Hospital
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Patient Questions Answered
CancerFax begins by reviewing your complete medical records โ pathology, imaging, treatment history, and biomarker results. Our clinical team identifies the most appropriate FUSCC department and specialist based on your cancer type, and prepares a structured oncology summary in the format expected by FUSCC for case triage.
We contact FUSCC's International Patient Office on your behalf, confirm specialist availability, obtain a treatment plan and cost estimate, and arrange a consultation appointment โ either in-person or via video call before you commit to travel. Once you decide to proceed, CancerFax arranges the medical visa invitation letter, coordinates airport transfer and accommodation, and provides active in-country support throughout your stay. After treatment, we translate discharge documents for your home oncologist and assist with follow-up scheduling.
FUSCC is a comprehensive cancer-only hospital with dedicated departments covering all major solid tumour types โ breast (nationally recognised centre of excellence), gastric, colorectal, hepatic, pancreatic, thoracic, head and neck, gynaecological, and urological cancers โ as well as haematological malignancies, lymphoma, sarcoma, and rare tumours. Breast cancer, radiation oncology, and pancreatic surgery carry national key specialty designations. The integrated Proton and Heavy Ion Hospital in Pudong serves patients requiring highly precise radiation therapy across tumour types.
Three factors distinguish FUSCC: institutional depth (93 years as China's only dedicated cancer hospital since 1931), international integration (eight formal sister-institution partnerships with global top-tier cancer centres including MD Anderson, Gustave Roussy, and Princess Margaret), and infrastructure breadth (proton and heavy ion therapy, three national key laboratories, 43 clinical departments, and 300+ annual SCI publications). For complex, rare, or internationally difficult-to-treat cancers, FUSCC's combination of research leadership and clinical scale is unmatched in China.
Yes. FUSCC's Pudong campus hosts the Shanghai Proton and Heavy Ion Hospital โ the first proton and carbon ion therapy facility in mainland China. The facility treats a range of cancers where the precision of charged particle therapy is particularly valuable, including skull base and spinal tumours, paediatric cancers, head and neck malignancies, liver tumours, and prostate cancer. CancerFax coordinates pre-assessment for proton/heavy ion therapy eligibility as part of the standard case review for patients considering this modality.
CancerFax manages the pre-travel record review process entirely. You submit your records (pathology, imaging, treatment history) to CancerFax via our secure portal or by email. We prepare a structured oncology summary and submit it to the relevant FUSCC department. The specialist conducts a document-based or video pre-screening consultation โ confirming eligibility, outlining the proposed treatment approach, and providing a cost estimate โ before you commit to travel. This removes the risk of arriving in Shanghai without a confirmed plan.
Access Fudan University Shanghai Cancer Center via CancerFax
Our clinical team reviews your records, prepares a structured summary for FUSCC's tumour board, confirms specialist availability, and arranges your consultation โ so you arrive with a clear plan.